The drug maker's consolidated net profit jumped 317.70% to Rs 2,946.32 crore on a 9.5% rise in net sales at Rs 6,353.13 crore in Q3 December 2020 over Q3 December 2019.
Consolidated profit before tax (PBT) soared 326.90% to Rs 4,005.40 crore in Q3 December 2020 as against Rs 938.17 crore in Q3 December 2019. Current tax expense for the quarter surged 397.80% to Rs 1,083.15 crore as against Rs 217.17 crore in Q3 December 2019. The Q3 result was declared after trading hours yesterday, 10 February 2021.
EBITDA grew 13.3% to Rs 1368.60 crore in Q3 FY21 over Rs 1208 crore in Q3 FY20. EBITDA margin stood at 21.5% in Q3 December 2020 as against 20.5% in Q3 December 2019.
Formulation revenue for the quarter recorded a growth of 11.3% Y-o-Y to Rs 5,682.40 crore and accounted for 89.3% of total revenues.
Anti-retrovirals (ARVs) business revenue for Q3 FY21 was was at Rs 443.40 crore as compared to Rs 313.40 crore in Q3 FY20, an increase of 41.5% Y-o-Y and accounted for 7% of revenue. The increased conversion from TLE to TLD across the geographies has led to the growth.
In Q3 FY21, API business posted a revenue of Rs 682.50 crore and contributed 10.7% to the consolidated revenue. Research & Development (R&D) spend stood at Rs 390.50 crore during the quarter, which is, 6.1% of revenues. The pharmaceutical firm also filed 2 DMFs with USFDA during the quarter. The company received final approval for 13 ANDAs from USFDA including 9 injectables.
Commenting on the Q3 FY21 performance, N. Govindarajan, the managing director (MD) of the company, has said that: "We maintained growth momentum in our revenue and profitability despite COVID challenges. We are witnessing a steady progress in our specialty pipeline and continue to focus on growing our business, improving efficiencies and productivity."
The board has approved an interim dividend of Rs 1.50 per equity share. The company has fixed 23 February 2021 as the record date.
Shares of Aurobindo Pharma fell 1.13% to Rs 956.90. Aurobindo Pharma manufactures generic pharmaceuticals and active pharmaceutical ingredients.
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU